Skip to main content
Sign In

University of Colorado Cancer Center

University of Colorado Cancer Center, A National Cancer Institute-designated Comprehensive Cancer Center

Thomas Flaig, MD



Genitourinary (GU) malignancies


Medical Oncology


University of Colorado Anschutz Medical Campus


Must have completed two years of college

Number of Openings: 1


Develop new therapies for the treatment of urologic cancers


Our laboratory is exploring multiple new methods for treating urologic cancers.  Bladder cancer is a significantly neglected cancer in terms of research attention. While it is the sixth most common cancer in humans, there have been no major treatment improvements in the last couple of decades. 

In superficial bladder cancer, we continue to use the only modestly effective treatments discovered in the 1970’s. Our work in looking for new treatment approaches includes integration of nano-technology, toxic fusion protein therapy and small molecule inhibitors testing. Another major thrust in our group is the use of microRNA expression to predict and better understand traditional chemotherapy resistance in bladder cancer. 

We also have active research projects in the characterization and treatment of prostate cancer, with potential opportunities in that area as well.  We are currently examining the causes of resistance to highly active androgen therapy.  Past and some ongoing projects in prostate cancer have included the evaluation of natural products to treat prostate cancer. 

Opportunities for summer students include bench work focused on the evaluation of new treatments with a focus on cell culture technique and cell viability.  Other techniques such as QT-PCR and Western blotting may be utilized as needed.


© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.